What to Expect at Asia-Pacific’s Only Drug-Diagnostic Co-Development Forum
您会看到什么 | 見どころ | Apa yang Diharapkan
As APAC grows as an emerging global hub for precision medicine innovation, the 2nd World Companion Diagnostics & Liquid Biopsy Summit APAC spotlights the region’s latest advances in biomarker-guided trials, CDx regulation, and cross-border co-development to accelerate access to precision therapies across oncology and beyond. Uniting local and global decision makers from biopharma, healthcare institutions, regulatory agencies, diagnostic developers, and testing labs, this summit empowers scalable, timely, and equitable diagnostic access for diverse patient populations across the region.

Unmissable Event Highlights
Advance Novel Biomarker Discovery & Validation
Improve patient selection and monitoring across solid and hematologic tumors with ctDNA, MRD and CTCs to organoid models and multiplex assays with AstraZeneca, Johnson & Johnson and OBI Pharma
Optimize Biomarker-Driven Trials
Navigate regional and global biomarker-driven trials with centralized and decentralized vendor networks to support both localized patient recruitment and global co-development success for CDx programs with Chugai Pharmaceuticals and Gilead Sciences
Fuel Precision Medicine Beyond Oncology
Uncover precision medicine applications in neurologic, chronic and rare diseases with gene panels, digital and multiplex biomarkers for earlier detection, improved stratification, and enhanced patient access to targeted therapies with FIND and Takeda
De-Risk Regulatory Filing & Launch
Decode IVD regulation and commercialization across fragmented APAC jurisdictions and shifting global LDT and IVDR compliance through proactive engagement with regional competent and notified bodies to unlock timely and equitable access with TÜV SÜD and ARPA
Attending Companies Include








